Table 2.

Risk of clinical outcomes according to quartiles of sTREM2 in the acute phase of ischemic stroke

	sTREM2, pg/mL				p trend
	< 247.45	247.45–401.27	401.27–651.60	≥ 651.60
Median (pg/mL)	172.16	323.62	503.15	901.40
The primary outcome: death or cardiovascular events
No. of cases (%)	56 (6.8)	63 (7.7)	66 (8.0)	103 (12.6)	< 0.001
Unadjusted HR	1.00	1.13 (0.79–1.61)	1.19 (0.83–1.70)	1.93 (1.40–2.68)	< 0.001
Multiple-adjusted HR*	1.00	1.01 (0.70–1.46)	1.01 (0.70–1.45)	1.57 (1.11–2.21)	0.002
Death
No. of cases (%)	32 (3.9)	31 (3.8)	45 (5.5)	78 (9.5)	< 0.001
Unadjusted HR	1.00	0.97 (0.59–1.59)	1.43 (0.91–2.24)	2.56 (1.69–3.86)	< 0.001
Multiple-adjusted HR *	1.00	0.76 (0.46–1.25)	1.06 (0.67–1.69)	1.68 (1.09–2.60)	< 0.001
Cardiovascular events
No. of cases (%)	39 (4.7)	47 (5.7)	40 (4.9)	54 (6.6)	0.19
Unadjusted HR	1.00	1.21 (0.79–1.85)	1.04 (0.67–1.61)	1.46 (0.97–2.21)	0.09
Multiple-adjusted HR *	1.00	1.14 (0.74–1.75)	0.97 (0.62–1.52)	1.36 (0.88–2.10)	0.17
Death or severe disability
No. of cases (%)	76 (9.4)	97 (12.1)	103 (13.0)	145 (18.6)	< 0.001
Unadjusted OR	1.00	1.32 (0.96–1.81)	1.43 (1.05–1.96)	2.19 (1.63–2.95)	< 0.001
Multiple-adjusted OR *	1.00	1.14 (0.80–1.64)	1.09 (0.76–1.56)	1.53 (1.08–2.18)	0.01
Severe disability
No. of cases (%)	44 (5.7)	66 (8.5)	58 (7.8)	67 (9.5)	0.01
Unadjusted OR	1.00	1.55 (1.04–2.30)	1.40 (0.93–2.09)	1.75 (1.18–2.59)	0.02
Multiple-adjusted OR*	1.00	1.39 (0.90–2.15)	1.10 (0.71–1.72)	1.40 (0.90–2.19)	0.29

sTREM2 soluble triggering receptor expressed on myeloid cells 2, HR hazard ratio, OR odds ratio

^* Adjusted for age, sex, current smoking, alcohol drinking, time from onset to randomization, admission NIHSS score, systolic blood pressure, high-sensitivity C-reactive protein, history of hypertension, hyperlipidemia, coronary heart disease, and diabetes mellitus, use of antihypertensive and lipid-lowering medications, family history of stroke, stroke subtype and randomized treatment